Respiratory Infection Diagnostics Markets by Technology, Plex, Facility, Product and Region with COVID-19 Impact and Forecasting /Analysis (Including Executive and Consultant Guides) 2022 to 2026
“COVID-19 breaks open POC markets. Technologies compete for diagnostics gold rush….”
COVID-19 has broken open the market for point of care testing of respiratory infections. Now the competition for market share begins in earnest. Large new markets are opening up; In health facilities, clinics, physicians’ offices and elsewhere. And lets not forget the screening market, not just for COVID, but for the other 20+ respiratory pathogens also.
New technology is forever changing the diagnosis of respiratory infections. Shrinking time to result is opening up markets multiple times the size of current microbiology based practice. Diagnosis has already moved into the Emergency Room and it's now moving to the physician’s lab. Could the home be next?
The multiplex factor is creating market confusion while lowering costs and improving care, but important factors are holding back progress. The widespread nature of respiratory infections, (young people can get 8 colds a year) means that potential market sizes are enormous. Respiratory (already the largest infectious disease category) will multiply in size. This is a huge growth opportunity for all diagnostic companies. Understand the opportunity and the risk with this new in-depth report.
If a country forecast is not already listed, purchasers can request individual country market size information, or other customization without additional charge with the corporate license.
Subscribe and Save
By signing up for the annual subscription, updates to this report will be automatically provided free of charge for a period of one year from initial purchase. These updates can include revised forecasts as markets increase or contract and exclusive market commentary not seen anywhere else. With the effects of COVID-19 being felt across all markets it has never been more crucial to stay fully informed with real-world actionable data. Subscribe to this report and receive ongoing market forecasting and analysis for sharpened strategic planning throughout the year.
- Quarterly report updates
- Summary of significant developments and market changes
- Phone consultation and assistance on request for the duration of the subscription
ABOUT THE LEAD AUTHOR
Mr. Greg Powell, B.SC., M.B.A is an experienced business and clinical professional. He is co-author of the paper "The Radioimmunoassay of Angiotensinogen by Antibody Trapping." He has worked in laboratory testing and management for over 20 years. Mr. Powell’s education includes:
- B.Sc. (Chemistry) University of BC
- M.B.A. (Finance and Policy) University of BC
- Market Research Seminar - Burke Institute
- Finance for Senior Executives - Harvard Business School